Skip to content
10-Q

Quarterly Report

Kiromic Biopharma, Inc.

0001437749-24-034182

← back to feed
Filed
Nov 8, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 6, 2024 1.55M sh
Capex Q3 2024 · Sep 30, 2024 $338K
Capex restated Q3 2024 · Sep 30, 2023 $98K
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$15.81M
Operating Cash Flow restated Q3 2024 · Sep 30, 2023 −$15.82M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.92M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $3.2M
Cash And Equivalents restated Q3 2024 · Sep 30, 2023 $4.38M
Stockholders Equity Q3 2024 · Sep 30, 2024 −$9.29M
Stockholders Equity Q3 2024 · Jun 30, 2024 −$5.17M
Stockholders Equity Q3 2024 · Mar 31, 2024 −$7.21M
Stockholders Equity Q3 2024 · Dec 31, 2023 −$9.12M
Stockholders Equity restated Q3 2024 · Sep 30, 2023 −$4.49M
Stockholders Equity restated Q3 2024 · Jun 30, 2023 −$6.3M
Stockholders Equity restated Q3 2024 · Mar 31, 2023 −$8.14M
Stockholders Equity restated Q3 2024 · Dec 31, 2022 −$5.78M
Current Liabilities Q3 2024 · Sep 30, 2024 $19.13M
Current Liabilities Q3 2024 · Dec 31, 2023 $20.38M
Total Liabilities Q3 2024 · Sep 30, 2024 $19.53M
Total Liabilities Q3 2024 · Dec 31, 2023 $21.29M
Current Assets Q3 2024 · Sep 30, 2024 $4.3M
Current Assets Q3 2024 · Dec 31, 2023 $4.43M
Total Assets Q3 2024 · Sep 30, 2024 $10.25M
Total Assets Q3 2024 · Dec 31, 2023 $12.17M
Sga Expense Q3 2024 · Sep 30, 2024 $2.38M
Sga Expense Q3 2024 · Sep 30, 2024 $6.68M
Sga Expense restated Q3 2024 · Sep 30, 2023 $2.88M
Sga Expense restated Q3 2024 · Sep 30, 2023 $7.9M
Rd Expense Q3 2024 · Sep 30, 2024 $4.23M
Rd Expense Q3 2024 · Sep 30, 2024 $11.39M
Rd Expense restated Q3 2024 · Sep 30, 2023 $2.68M
Rd Expense restated Q3 2024 · Sep 30, 2023 $6.72M
Net Income Q3 2024 · Sep 30, 2024 −$7.44M
Net Income Q3 2024 · Sep 30, 2024 −$20.41M
Net Income Q3 2024 · Jun 30, 2024 −$6.83M
Net Income Q3 2024 · Mar 31, 2024 −$6.15M
Net Income restated Q3 2024 · Sep 30, 2023 −$4.19M
Net Income restated Q3 2024 · Sep 30, 2023 −$16.26M
Net Income restated Q3 2024 · Jun 30, 2023 −$6.76M
Net Income restated Q3 2024 · Mar 31, 2023 −$5.3M
Operating Income Q3 2024 · Sep 30, 2024 −$6.6M
Operating Income Q3 2024 · Sep 30, 2024 −$18.07M
Operating Income restated Q3 2024 · Sep 30, 2023 −$5.55M
Operating Income restated Q3 2024 · Sep 30, 2023 −$14.62M
Revenue Q3 2024 · Sep 30, 2024 $0